SHBG, a hepatic glycoprotein that transports testosterone and other steroids in the circulation, has emerged as a promising biomarker for assessing MetS risk due to its strong associations with key metabolic indicators such as IR, adiposity, and dyslipidemia. The gene discussed is SHBG; the disease is metabolic syndrome.